Baseline differences in characteristics and risk behaviors among people who inject drugs by syringe exchange program modality: an analysis of the Miami IDEA syringe exchange.
Adolescent
Adult
Aged
Female
Florida
Harm Reduction
Hepatitis C
/ complications
Ill-Housed Persons
Humans
Income
Male
Middle Aged
Needle-Exchange Programs
/ statistics & numerical data
Risk-Taking
Sex Factors
Socioeconomic Factors
Substance Abuse, Intravenous
/ psychology
Surveys and Questionnaires
Unemployment
White People
Young Adult
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
23 01 2019
23 01 2019
Historique:
received:
09
10
2018
accepted:
15
01
2019
entrez:
25
1
2019
pubmed:
25
1
2019
medline:
23
5
2020
Statut:
epublish
Résumé
In March of 2016, Florida passed the Infection Disease Elimination Act (IDEA), legalizing the formation of the first syringe exchange program in Florida, which opened in December of 2016 at a fixed site in Overtown, Miami. Since that time, the exchange expanded in April of 2017 to include a mobile van unit that provides the same services at different locations throughout Miami-Dade County. Trained interviewers conducted face-to-face interviews from all first-time participants at the IDEA Exchange, both at the fixed site and the mobile van unit. Among 718 first-time enrollees, 74.8% were male, 52.1% were non-Hispanic White, 85.9% completed high school, 59.8% were unemployed, 42.1% were homeless, 54.2% reported an annual income of less than $15,000, and the mean age was 38 years. Participants at the fixed site and mobile van unit reported differences in socioeconomic status, injection drug-related behaviors, and pre-existing hepatitis C virus (HCV) infection status. Taken together, these results suggest that the mobile unit is capturing a subset of PWID in Miami that the fixed site is not, and vice-versa. As the opioid crisis extends into all demographics, such multimodal efforts to target various populations of PWID should be kept in mind, especially when unveiling future syringe exchanges in Florida and other late-adopting states.
Sections du résumé
BACKGROUND
In March of 2016, Florida passed the Infection Disease Elimination Act (IDEA), legalizing the formation of the first syringe exchange program in Florida, which opened in December of 2016 at a fixed site in Overtown, Miami. Since that time, the exchange expanded in April of 2017 to include a mobile van unit that provides the same services at different locations throughout Miami-Dade County.
METHODS
Trained interviewers conducted face-to-face interviews from all first-time participants at the IDEA Exchange, both at the fixed site and the mobile van unit.
RESULTS
Among 718 first-time enrollees, 74.8% were male, 52.1% were non-Hispanic White, 85.9% completed high school, 59.8% were unemployed, 42.1% were homeless, 54.2% reported an annual income of less than $15,000, and the mean age was 38 years. Participants at the fixed site and mobile van unit reported differences in socioeconomic status, injection drug-related behaviors, and pre-existing hepatitis C virus (HCV) infection status.
CONCLUSIONS
Taken together, these results suggest that the mobile unit is capturing a subset of PWID in Miami that the fixed site is not, and vice-versa. As the opioid crisis extends into all demographics, such multimodal efforts to target various populations of PWID should be kept in mind, especially when unveiling future syringe exchanges in Florida and other late-adopting states.
Identifiants
pubmed: 30674334
doi: 10.1186/s12954-019-0280-z
pii: 10.1186/s12954-019-0280-z
pmc: PMC6343273
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7Références
Public Health Rep. 1998 Jun;113 Suppl 1:75-80
pubmed: 9722812
PLoS One. 2015 Jun 15;10(6):e0129360
pubmed: 26075888
Subst Use Misuse. 1998 Apr;33(5):1173-96
pubmed: 9596382
Int J STD AIDS. 1996;7 Suppl 2:57-61
pubmed: 8799797
N Engl J Med. 2016 Jan 14;374(2):154-63
pubmed: 26760086
Harm Reduct J. 2007 Oct 24;4:14
pubmed: 17958894
J Urban Health. 2009 Jan;86(1):132-54
pubmed: 19015995
Am J Public Health. 2018 Feb;108(2):182-186
pubmed: 29267060
Lancet. 1997 Mar 1;349(9052):604-8
pubmed: 9057732
J Acquir Immune Defic Syndr. 2000 May 1;24(1):57-61
pubmed: 10877496
Annu Rev Public Health. 2015 Mar 18;36:559-74
pubmed: 25581144
Subst Use Misuse. 2006;41(6-7):835-6
pubmed: 16809172
JAMA. 1994 Jan 12;271(2):115-20
pubmed: 8264065
JAMA Psychiatry. 2014 Jul 1;71(7):821-6
pubmed: 24871348
Drug Alcohol Depend. 2012 Jun 1;123(1-3):255-9
pubmed: 22209091
Harm Reduct J. 2018 Feb 8;15(1):6
pubmed: 29422042